Table 1 Demographic data (n = 9).
From: Activated type 17 helper T cells affect tofacitinib treatment outcomes
Mean (SD) or n (%) | |
|---|---|
Age, y | 37.4 (16.4) |
Female | 3 (33.3) |
BMI, kg/m2 | 20.5 (3.3) |
Duration of disease, m | 91.4 (107.8) |
Current smoker | 0 (0) |
Disease location | |
Total colitis | 7 (77.8) |
Left-sided colitis | 2 (22.2) |
Proctitis | 0 |
Previous exposure to advanced therapies (number) | 1.3 (0.5) |
Previous exposure to advanced therapies (agents) | |
Anti-TNF | 6 (66.7) |
Tacrolimus | 2 (22.2) |
Anti-integrin | 2 (22.2) |
IL-12/IL-23 antagonist | 1 (11.1) |
JAK inhibitor | 0 (0) |
Concomitant medications | |
5-ASA | 8 (88.9) |
Corticosteroids | 1 (11.1) |
Clinical score | |
Partial Mayo score | 5.8 (2.3) |
Endoscopic Mayo score | 2.7 (0.5) |
Laboratory test | |
C-reactive protein, mg/dl | 2.1 (3.0) |
Albumin, g/dl | 3.6 (0.8) |
Hemoglobin, g/dl | 12.3 (1.8) |
